Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Reverses View On Perjeta In Breast Cancer After Roche's Price Cut

Executive Summary

The UK's HTA NICE says it is now backing Roche's Perjeta (pertuzumab) to treat a certain form of breast cancer on the publicly funded NHS after Roche offered a price discount.

Advertisement

Related Content

NICE Turns Attention To Roche's Perjeta After Finally Passing Kadcyla For Breast Cancer
NICE Attention Turns To Roche's Perjeta After Finally Passing Kadcyla
UK Reimbursement Decisions Focus Mostly On Cancer
Is ICER Too NICE? A Comparison Of Drug Assessments Programs
Outdated System Preventing Breast Cancer Patients Getting Access To Early Treatment In England, Says Roche
Frustrated Roche Hopes NICE Will Eventually Back Kadcyla

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097694

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel